What it's for (Indications)
- Bamifylline is a methylxanthine derivative primarily indicated for the symptomatic treatment of various obstructive respiratory diseases where bronchodilation is desired.
- This includes chronic obstructive pulmonary disease (COPD), bronchial asthma, and other conditions characterized by reversible airflow obstruction.
- Its use aims to alleviate bronchospasm, improve pulmonary function, and reduce respiratory distress, thereby enhancing the patient's quality of life.
- The clinical application targets the maintenance treatment rather than acute exacerbations, providing sustained relief from airway narrowing and associated symptoms such as wheezing, shortness of breath, and chest tightness.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of bamifylline must be individualized based on the patient's clinical response, tolerance, and serum concentrations where available, although therapeutic drug monitoring is less common for bamifylline than for theophylline. Typical oral dosages for adults might range, for example, from 300 mg to 600 mg administered two to three times daily, depending on the specific formulation (e.g., immediate-release vs. sustained-release) and the patient's overall clinical picture. Factors such as age, renal and hepatic function, concomitant medications, and smoking status can significantly influence the pharmacokinetics and necessitate dose adjustments to optimize therapeutic benefit while minimizing adverse effects. It is crucial to start with a lower dose and titrate upwards as tolerated under medical supervision. |
Safety & Warnings
Common Side Effects
- Bamifylline, like other xanthine derivatives, can induce a range of side effects, primarily dose-related.
- Common adverse reactions affect the gastrointestinal system (e.
- g.
- , nausea, vomiting, abdominal discomfort, dyspepsia) and the central nervous system (e.
- g.
- , headache, insomnia, restlessness, tremors, irritability).
- Cardiovascular effects may include palpitations, tachycardia, and arrhythmias, especially at higher doses or in susceptible individuals.
- Other less frequent but serious adverse events can involve seizures, hypotension, and hypersensitivity reactions.
- Patients should be advised to report any persistent or severe side effects to their healthcare provider promptly, as dose reduction or discontinuation might be necessary to manage these symptoms effectively and prevent toxicity.
Serious Warnings
- Black Box Warning: Bamifylline does not carry a formal FDA-mandated Black Box Warning. However, a **Serious Warnings** section is warranted due to the inherent risks associated with xanthine derivatives. Bamifylline, like theophylline, has a relatively narrow therapeutic index, meaning the difference between effective and toxic doses is small. Overdose or rapid increases in dosage can lead to severe and potentially fatal adverse reactions, including cardiac arrhythmias (e.g., ventricular tachycardia, fibrillation) and convulsions. Factors such as age, liver disease, congestive heart failure, and concurrent medications can significantly alter drug clearance, leading to accumulation and toxicity. Therapeutic drug monitoring, while less common for bamifylline, may be considered in high-risk patients to ensure safe and effective plasma concentrations and minimize the potential for severe adverse events.
- Bamifylline should be used with extreme caution in patients with pre-existing cardiovascular conditions, including severe hypertension, arrhythmias, or recent myocardial infarction, due to its potential to exacerbate these conditions.
- Patients with hyperthyroidism, peptic ulcer disease, or epilepsy also require careful monitoring.
- Hepatic or renal impairment can significantly alter bamifylline's metabolism and excretion, necessitating dose adjustments to avoid accumulation and toxicity.
- Concurrent use of other drugs that inhibit its metabolism (e.
- g.
- , cimetidine, erythromycin, some fluoroquinolones) can increase serum levels and the risk of adverse effects, while inducers (e.
- g.
- , phenobarbital, phenytoin, rifampicin) can decrease levels.
- Patients should avoid smoking, as it can reduce bamifylline efficacy.
How it Works (Mechanism of Action)
Bamifylline's therapeutic effects as a bronchodilator are primarily mediated through its action as a non-selective phosphodiesterase (PDE) inhibitor. By inhibiting various PDE isoenzymes, particularly PDE3 and PDE4 in bronchial smooth muscle cells, it leads to a reduction in the breakdown of cyclic adenosine monophosphate (cAMP). The consequent increase in intracellular cAMP levels activates protein kinase A (PKA), which then phosphorylates various proteins, leading to a decrease in intracellular calcium and ultimately relaxation of the bronchial smooth muscle. Furthermore, bamifylline exhibits adenosine receptor antagonism, which may contribute to its bronchodilatory and anti-inflammatory effects, as adenosine can induce bronchoconstriction and inflammation.
Commercial Brands (Alternatives)
No other brands found for this formula.